Quick Answer
ADC Therapeutics SA reported Total Revenue of $81.36 million for fiscal year 2025.
ADC Therapeutics SA Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $81.36M | +14.9% |
| 2024 | $70.84M | +1.8% |
| 2023 | $69.56M | -66.9% |
| 2022 | $209.91M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $16.43M | -11.0% | -12.8% |
| June 30, 2025 | $18.84M | +8.2% | -18.2% |
| March 31, 2025 | $23.03M | +27.6% | +24.7% |
| September 30, 2024 | $18.46M | +27.4% | +6.1% |
| June 30, 2024 | $17.41M | -9.7% | -3.6% |
| March 31, 2024 | $18.05M | -4.9% | +24.6% |
| September 30, 2023 | $14.49M | — | -24.8% |
| June 30, 2023 | $19.28M | — | +1.5% |
- ADC Therapeutics SA showed an increase of +14.9% in Total Revenue compared to the prior fiscal year.
- Over the 2022–2025 period, ADC Therapeutics SA’s total revenue has declined by 61.2% (from $209.91 million to $81.36 million).
- The most recent figure is from ADC Therapeutics SA’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: